Reducing Solid Oral Dose Recall Risk Without Revalidation

1. Executive Summary

Solid oral dosage (SOD) manufacturing, particularly of tablets and capsules, faces persistent structural inspection risks that current quality control methods struggle to fully mitigate. FDA recall data continue to show that manufacturing issues in these dosage forms, such as labeling mix-ups, contamination, and physical tablet/capsule defects, regularly lead to costly product recalls [1]. Even well-established inspection regimes can fail to catch all defects. Manual visual inspection, in particular, is inherently prone to inconsistency and human error, and post-production sampling methods can miss many defects simply because only a fraction of units are examined [2]. These undetected defects, or “inspection escapes,” highlight a structural challenge in pharmaceutical quality assurance: despite compliance with current good practices, a small number of defective units can slip through to the market, jeopardizing patient safety and company compliance.

This white paper introduces the Sentinel Model for secondary inspection as a pragmatic solution to significantly reduce recall risk in SOD manufacturing without disrupting existing processes. The Sentinel Model is conceived as an independent, second-layer inspection mechanism that runs in parallel to primary (existing) inspections. It is deliberately engineered as a non-disruptive, non-decision-making layer: it continuously monitors for potential defects or anomalies but does not directly make batch quality decisions or alter the validated production flow. Because the Sentinel layer operates in an observational capacity, without modifying any process parameters or product acceptance criteria, it may be deployed without triggering costly revalidation or requiring changes to regulatory filings when drug manufacturers justify it through documented risk assessment and change control. In essence, the Sentinel approach serves as an ever-vigilant guardian over the line, strengthening the overall risk posture by catching issues that primary inspections might miss, all while the established workflow and approvals remain undisturbed. This allows us to materially reduce recall risk on legacy assets without pausing production or reopening filings. Final determination regarding validation and regulatory impact remains the responsibility of the manufacturer and its quality unit.

Aligning with ICH Q9 and Q10 principles, this secondary inspection strategy exemplifies modern quality risk management and quality system continuous improvement. It adds a robust risk mitigation step that bolsters the pharmaceutical quality system in a manner consistent with regulatory expectations. By providing enhanced oversight without supplanting existing controls, the approach supports industry modernization goals within the framework of current Good Manufacturing Practice (cGMP) compliance. Regulators and auditors may view the Sentinel Model’s emphasis on early detection and prevention of defects as being in line with ICH Q10’s vision of an effective, continuously improving quality system [3], implemented here in a practical, low-impact way.

Crucially, the Sentinel Model complements rather than replaces existing inspection processes. It is added alongside manual inspectors or automated vision systems as an additional safeguard, ensuring that any quality issue escaping the primary inspection has another opportunity for detection. This layered defense significantly reduces the likelihood of defective tablets or capsules reaching patients, thereby protecting consumers and preserving manufacturer trust. At the same time, it leaves the proven, validated inspection workflow intact, maintaining the familiarity and reliability of current procedures for operators and quality teams. The result is a meaningful increase in quality assurance with minimal disruption: manufacturers gain an extra safety net against recalls and batch failures, without the operational downtime or regulatory burden that would normally accompany major process changes.

This paper details the development and application of the Sentinel Model across its full lifecycle. It presents a comprehensive literature review of inspection risks and recall trends, an analysis of relevant regulatory guidelines, and the key design principles underlying the Sentinel approach. Integration pathways are examined to illustrate how the sentinel layer can be deployed in both existing facilities and new production lines. Rigorous validation and compliance considerations are addressed to ensure that introducing this secondary layer adheres to cGMP requirements and does not compromise the validated state of the process. An economic rationale is also provided, showing how reducing recall incidence and waste through a sentinel layer can yield significant cost benefits and return on investment. Finally, real-world use cases demonstrate the model’s versatility and impact in different manufacturing scenarios.

The value proposition of the Sentinel Model resonates with all key stakeholders in pharmaceutical manufacturing. For regulatory authorities, it represents a proactive enhancement of quality assurance that operates fully within the established compliance framework. Quality leaders will recognize it as a pragmatic risk reduction strategy that addresses a known vulnerability (inspection escapes) while upholding the organization’s Quality by Design (QbD) principles and regulatory commitments. Manufacturing teams will appreciate that the sentinel layer integrates seamlessly into production, requiring no overhaul of procedures and minimal training, yet delivering a stronger safety net for product quality. And for pharmaceutical and CDMO executives, the approach offers a compelling business case: a relatively low-impact technical upgrade that can significantly decrease the probability of recalls, downstream liabilities, and associated costs, all without interrupting supply or needing extensive revalidation efforts when manufacturers justify it through risk assessment and change control.

In summary, Reducing Solid Oral Dose Recall Risk Without Revalidation: A Sentinel Approach to Secondary Inspection outlines a forward-looking but immediately actionable strategy for improving tablet and capsule manufacturing outcomes. By implementing a non-invasive secondary “sentinel” inspection layer, companies can substantially strengthen their quality risk posture and better protect patients as well as their own brands. This is achieved in a scientifically sound, regulator-endorsed manner that complements existing systems rather than overhauling them. The Sentinel Model stands as a clear example of how pharmaceutical manufacturers can advance toward “zero defects” and modernized quality systems, not by replacing what already works, but by intelligently augmenting it for the benefit of all stakeholders.

2. The Current Inspection Landscape in Solid Oral Dose Manufacturing

Visual inspection remains a foundational control in solid oral dose manufacturing, particularly for tablets and capsules produced on legacy and high-mix production lines. Despite advances in process control and manufacturing science, manual inspection continues to play a central role due to its flexibility, familiarity, and historical validation within established quality systems.

In a typical workflow, manual visual inspection is positioned downstream of compression or encapsulation and prior to final packaging. Trained inspectors evaluate product against defined defect criteria under controlled conditions, following validated procedures that specify inspection rates, environmental requirements, training qualifications, and acceptance thresholds. These processes are often deeply embedded within site SOPs and validation documentation, having evolved incrementally over many years.

For many manufacturers and CDMOs, manual inspection persists not because it is considered optimal, but because it is operationally adaptable. Solid oral dose production frequently involves:

• High product mix and frequent changeovers
• Variable tablet shapes, colors, and imprints
• Short production campaigns with limited run lengths

Under these conditions, fully automated inspection solutions can introduce complexity related to setup, validation scope, and line integration. Manual inspection, by contrast, offers rapid reconfiguration and a well-understood compliance profile, making it the default choice for many sites despite its known limitations.

From a regulatory perspective, manual inspection processes are generally viewed as acceptable when properly validated, executed, and monitored. Inspections and audits typically focus on:

• Adequacy of inspector training and qualification
• Environmental controls and ergonomics
• Inspection rate justification and fatigue management
• Documentation, deviation handling, and trend analysis

However, regulatory acceptance does not equate to risk elimination. Inspection outcomes from regulatory audits and post-market surveillance indicate that inspection-related escapes can and do occur even in facilities with mature quality systems. These events often reflect cumulative system pressures rather than discrete procedural failures.

Additionally, the effectiveness of manual inspection is inherently sensitive to operational variability. Factors such as staffing constraints, overtime, throughput demands, and production scheduling can subtly influence inspection performance without necessarily triggering deviations or nonconformances. Over time, these pressures can erode the margin of safety that manual inspection is expected to provide.

As a result, many manufacturers find themselves in a challenging position. Manual inspection processes are validated, regulatorily accepted, and operationally entrenched, yet they remain a recognized source of residual risk. Addressing that risk through wholesale replacement of inspection systems is often impractical due to cost, disruption, and revalidation requirements.

This tension between regulatory acceptance and operational reality defines the current inspection landscape in solid oral dose manufacturing. It sets the stage for exploring how additional layers of oversight, when carefully designed, can strengthen inspection confidence without dismantling the validated systems already in place.

Callout: Where Inspection Escapes Most Often Occur

3. Recall Frequency, Cost, and Operational Impact

FDA Inspection and Recall Data Highlights

Analysis of publicly available inspection and recall data from the U.S. Food and Drug Administration reveals a persistent and growing structural risk in U.S. drug manufacturing, particularly for solid oral dosage forms.

Inspection Pressure Is Widespread and Ongoing

Across Maryland, Delaware, New Jersey, and Pennsylvania alone, FDA inspections over the last five years have resulted in over 1,000 individual citation observations. These citations are not isolated events, but recurring indicators of operational strain at manufacturing sites. Many are associated with quality systems, process controls, and inspection effectiveness, especially at facilities operating long-running, fully validated production lines.

Importantly, inspection citations are far more common than recalls. Most sites will never experience a public recall, yet many operate under continuous regulatory scrutiny and repeated inspection observations. This creates a sustained environment of risk sensitivity, internal remediation effort, and limited operational flexibility.

Drug Recalls Are Increasing, Not Declining

The figures mentioned in this section reflect publicly available FDA recall data and are subject to classification, reporting lag, and evolving regulatory definitions. Review of the FDA’s official drug recall database shows 129 drug recalls over the past several years. Rather than trending downward, recall frequency has accelerated since 2023, with 2024 representing the highest year on record for total drug recalls. Early 2025 data indicates that elevated recall activity is continuing.

This trend suggests that existing quality and inspection strategies are not keeping pace with modern regulatory expectations, even for well-established products.

Solid Oral Dosage Forms Are Disproportionately Affected

Of the 129 total drug recalls analyzed, 41 involved solid oral dosage forms, including tablets and capsules. Solid-dose products therefore account for approximately one-third of all drug recalls, despite being widely regarded as mature, well-understood dosage forms.

Solid oral dose recalls have increased sharply since 2023, with 2024 alone accounting for 17 tablet and capsule recalls, the highest level observed in the dataset. This rise outpaces the growth rate of overall drug recalls, indicating a specific and growing vulnerability in solid-dose manufacturing.

The Structural Root Cause

Many of these recalls and inspection findings involve:

• Failed dissolution or out-of-specification results
• Incorrect strength or content uniformity issues
• Cross-contamination and CGMP deviations

These are not novel formulation failures. They are process confidence failures occurring on legacy, fully validated manufacturing lines where inspection strategies were defined years ago and are difficult to modify without triggering revalidation.

Implication

The convergence of sustained inspection pressure and rising solid-dose recalls underscores a clear industry need: ways to increase inspection confidence on legacy tablet and capsule lines without altering validated processes or requiring revalidation.

This environment favors non-disruptive, post-process approaches that provide additional quality signals while preserving the validated state of existing manufacturing systems.

4. Regulatory Perspective on Inspection and Risk Mitigation

Regulatory agencies like the FDA and EMA emphasize a proactive, risk-based approach to pharmaceutical manufacturing quality. Current Good Manufacturing Practice (cGMP) regulations require companies to use up-to-date technologies and systems to ensure consistent product quality. Modern quality frameworks (e.g. ICH Q8-Q10) encourage manufacturers to identify potential risks to product quality and implement appropriate controls throughout the process. Quality Risk Management (QRM) principles, as outlined in ICH Q9, stress that risk-based decision-making is inherent in all quality risk management activities, forming the foundation for decisions on controlling and mitigating hazards. Regulators expect firms to not only comply with minimum requirements, but to continuously evaluate and strengthen their processes to prevent quality issues before they reach patients.

One key regulatory expectation is the prevention of labeling errors, mix-ups, and contamination. For example, U.S. regulations (21 CFR 211) mandate comprehensive near-100% unit-level examination or a validated automated system to ensure correct product labeling and packaging. Guidance also highlights the need for systems that prevent mix-ups and cross-contamination in production and packaging areas. These rules underscore that relying solely on end-product testing is insufficient: regulators want built-in quality and robust in-process controls to catch issues early.

FDA inspection findings and warning letters in recent years frequently cite inadequate oversight of manufacturing lines, especially on legacy equipment that may lack modern controls. In response, support for modernization initiatives has been increasing. The FDA’s 21st Century cGMP initiative and similar programs have encouraged adoption of advanced process monitoring, automation, and process analytical technology (PAT) to enhance quality control.

From a regulatory perspective, risk mitigation is paramount. Authorities expect that when new risks are identified, companies will implement effective CAPA (Corrective and Preventive Actions) to address root causes. Introducing additional or improved inspection steps is often viewed favorably as a preventive measure, provided those systems are validated and documented. Regulatory guidance consistently emphasizes that robust, risk-based inspection controls are a fundamental component of a compliant pharmaceutical quality system. Firms that proactively strengthen their inspection regimes demonstrate a state of control in manufacturing, which can reduce regulatory scrutiny and build confidence with both regulators and the public.

5. Limitations of Manual Inspection as a System

Manual inspection has long been a staple of pharmaceutical operations: line operators checking tablets and capsules by eye, or quality technicians inspecting samples from each batch. While human inspectors can be highly skilled and intuitive, a purely manual inspection system has inherent limitations. Fatigue, attention lapses, and human error can result in defects being missed. Studies show that human visual inspection has materially reduced effectiveness under sustained or repetitive conditions. This is a concern on high-speed solid dose production lines, where thousands of units are produced per hour.

Consistency and objectivity are also problematic with manual checks. Different inspectors may have varying thresholds for what constitutes a defect. Training and SOPs attempt to standardize this, but some level of subjectivity remains. Importantly, manual inspection is generally too slow and labor-intensive for comprehensive near-100% unit level examination of product units. Firms often must balance thoroughness with efficiency, meaning only a fraction of output (or intermittent samples) gets inspected by eye. This creates a risk that a nonconforming unit slips through unnoticed.

Recent FDA recall data underscores the gaps in manual and procedural inspection controls. There have been multiple cases of packaging or product mix-ups that were not caught at the manufacturing site. One example is a 2023 incident where a batch of capsules was found to contain the wrong product in the bottle, due to a labeling mix-up that went undetected until a pharmacist noticed the error. In another case, a major pharmaceutical firm had to recall immunosuppressant capsules because some bottles contained empty capsules, an error only identified after product release. These incidents highlight that manual inspections and standard in-process checks can and do fail, especially on legacy production lines.

In summary, while human inspectors provide valuable judgment and flexibility, a manual inspection system alone is prone to fatigue, inconsistency, and limits in sampling coverage. Modern quality expectations and high production volumes have stretched the manual approach to its limits. This sets the stage for augmenting or replacing certain manual tasks with more reliable, automated inspection to plug the gaps and ensure that no significant defect escapes into the supply chain.

6. Secondary Inspection as a Risk-Reduction Strategy

To address the shortcomings of any single inspection point, pharmaceutical manufacturers increasingly employ secondary inspection as a layered risk reduction strategy. The concept is simple: introduce an additional, independent check to catch defects or errors that the primary process might miss. In practice, secondary inspection can take various forms, from a second human verifier to an automated vision system, but the goal is the same: build redundancy into the quality control process so that a failure in one layer is caught by another.

One common application is in packaging and labeling operations. Given that labeling mix-ups and packaging errors have led to high-profile recalls, many firms now use technologies like barcoding and vision systems as a secondary check. For example, after tablets are bottled and labeled, a camera system might scan the bottle label and even the shape/color of visible tablets to confirm that the correct product is in the correct package.

Another area is in-process tablet inspection. A legacy solid dose line might rely on manual in-process checks. By adding a secondary automated inspection unit, every single tablet or capsule can be inspected for certain defects. Automated vision inspection excels at detecting tiny anomalies and does not suffer fatigue, providing a consistent second line of defense.

Importantly, the secondary inspection should be independent and ideally different in mechanism from the primary. This way, a single-mode failure won’t invalidate both layers. Secondary physical inspection is an extension of independent redundancy philosophies in pharmaceutical quality systems.

In essence, secondary inspection is about risk reduction: by catching what the first pass missed, it significantly lowers the residual risk of a serious quality defect. Many modern systems are now designed for human-machine collaboration, where automated inspection flags suspects and human inspectors verify exceptions.

7. The Sentinel Model: Design Principles

The “Sentinel Model” refers to a strategic framework for inspection that acts as an ever-vigilant guardian over the manufacturing line. In practical terms, a sentinel system is an integrated set of sensors, vision technologies, and analytics that continuously monitor product quality without relying on human intervention. Its design principles draw from the idea of a sentinel: always on guard, independent, and capable of raising an alarm at the first sign of trouble.

Independence and Redundancy

The sentinel operates in parallel to the main manufacturing process controls, not as a replacement but as an independent layer. It can detect failures or lapses in the primary system and provide redundancy such that no single point of failure dominates quality control.

Comprehensive near-100% unit-level inspection

Unlike sampling-based QC tests, the Sentinel Model aims for near-total coverage of units and critical process parameters. High-speed camera arrays and/or sensors should inspect every tablet or capsule for defined critical defects.

Real-time monitoring and alerts

The sentinel system continuously monitors in real time and flags anomalies immediately. Many implementations use advanced algorithms, including AI and machine learning, to analyze images or sensor data on the fly.

High sensitivity with low false positives

A well-designed sentinel must balance sensitivity and specificity. It should capture meaningful defects without overwhelming the process with false rejections.

Non-intrusive implementation

By design, a sentinel should not adversely affect the product or significantly slow down the line. It operates in a non-invasive manner, typically optical or sensor-based, avoiding direct contact that could introduce contamination or damage.

Flexibility and adaptability

The Sentinel Model is designed to handle a variety of products and scenarios. Switching between products should be streamlined with appropriate “recipes” or parameters for each SKU.

In summary, the Sentinel Model’s design principles revolve around creating an intelligent, autonomous guard for the production line that assures quality beyond what traditional manual or single-layer systems can achieve.

8. Integration Into Existing Manufacturing Lines

Integrating a Sentinel Model system into an existing (and often legacy) solid dose manufacturing line requires careful planning but can be done with minimal disruption. Most legacy lines are already validated and running near capacity, so any new addition must fit into the line physically and logically without causing excessive downtime or rework of equipment.

Identify optimal insertion points

Commonly, for tablets and capsules, this is either immediately after the tablet press/capsule filler or right before/at the packaging stage. The integration point is chosen based on risk: earlier catches defects before further value is added; later verifies correct product/package combination.

Mechanical and control integration

Physically, the sentinel module is portable in nature and designed to not be a permanent addition to an existing line. Control integration can be largely independent, avoiding deep entanglement with legacy PLC code, supporting the claim that it does not impact the proven sequence of the existing process.

Data integration and connectivity

While mechanically separate, the sentinel can be selectively integrated to facility systems depending on validation strategy. If avoiding revalidation is a priority, outputs are kept advisory and non-dispositive.

Ensuring throughput compatibility

A critical consideration is that the sentinel must handle line speed without becoming a bottleneck. Integration planning should ensure inspection speed and processing keep pace with production.

Minimal footprint and utility needs

Integration planning includes physical space, clearance for rejects collection, and utility requirements. Ideally, the system uses existing power and compressed air, minimizing facility changes.

Integration testing and phased rollout

Systems are often tested offline, then run in “shadow mode” to gauge performance, then put into active operation once proven to be stable and non-disruptive.

By following these integration practices, manufacturers can incorporate the Sentinel Model into existing solid dose lines without extensive re-engineering.

9. Validation, Revalidation, and Compliance Considerations

Any new inline system in a pharmaceutical manufacturing process must undergo thorough validation to meet regulatory compliance. However, because the Sentinel system does not do any of the following, manufacturers may consider it lower impact under risk-based change control. The Sentinel system does not:

• Make accept/reject decisions
• Alter the flow of product that determines disposition
• Replace or redefine the validated inspection method
• Write GMP records used for batch release
• Exist in SOP’s as a required inspection step
• Exist as part of the control strategy

The following characteristics are commonly used by manufacturers when assessing regulatory impact; they do not constitute regulatory determination. The Sentinel system does:

• Observe inspection outcomes after completion of validated inspection
• Identify units or inspection periods that may warrant secondary review
• Provide objective oversight of inspection consistency and performance
• Support quality review, trending, and continuous improvement activities
• Generate advisory, non-GMP information
• Enable risk-based focus of human inspection effort
• Function independently of the validated control strategy

IQ and OQ

Optional Verification Activities for Auxiliary, Post-Inspection Systems

Sentinel is designed to operate as a non-dispositive, post-inspection advisory system. As such, it may not require full equipment qualification (IQ/OQ/PQ), depending on documented risk assessment and intended use. However, CDMOs may elect to perform limited, risk-based verification activities to document proper installation and intended function. These activities are commonly referred to as IQ-lite and OQ-lite.

Sentinel IQ: Installation Verification (What CDMOs Typically Expect)

Purpose: To document that Sentinel is installed as intended and does not interfere with the validated inspection process.

Typical scope: IQ-lite focuses on presence, placement, and non-interference, not process qualification.

What IQ usually includes

• Verification that Sentinel is installed in the approved location
• Confirmation that product-contact parts match approved materials and drawings
• Verification that installation does not alter existing inspection equipment or product flow used for disposition
• Confirmation that required utilities (power, air, network) are connected and within specified ranges
• Identification and labeling of Sentinel as a non-GMP, auxiliary system
• Verification that Sentinel can be removed or bypassed without impacting batch release

What Sentinel IQ explicitly does not include

• No validation of inspection effectiveness
• No acceptance criteria tied to product quality
• No batch production runs
• No linkage to MES or batch records for disposition

What Sentinel Model firms supply to support IQ

• Installation drawings and footprints
• Material certifications for product-contact components
• Utility requirements and limits
• Non-interference and bypass description
• IQ-lite checklist template

Sentinel OQ: Functional Verification

Purpose: To demonstrate that Sentinel functions as designed without making or influencing quality decisions.

Typical scope: OQ verifies deterministic behavior, not inspection performance.

What OQ usually includes

• Verification that Sentinel powers on and operates reliably
• Confirmation that tablets can pass through without damage
• Verification that diversion to “secondary review” occurs consistently when triggered
• Confirmation that failure modes are safe (e.g., default to primary flow)
• Verification that outputs are advisory only and clearly labeled non-GMP
• Confirmation that Sentinel does not block, reject, or disposition product

What OQ explicitly does not include

• No defect detection validation
• No comparison against validated inspection results
• No sensitivity or specificity testing
• No statistical performance qualification
• No PQ batches

What Sentinel Model firms supply to support OQ

• Functional description of Sentinel behavior
• Expected responses to defined non-GMP stimuli
• Failure-mode and safe-state description
• OQ-lite functional test scripts
• Acceptance criteria focused on function, not quality outcomes

From a compliance standpoint, it is crucial to validate data integrity and software aspects if the sentinel is intended to affect GMP records of a batch (which may constitute revalidation). In a system where the Sentinel is an internal observer and not a writer of decision-making batch acceptance/rejection metrics, it may be compliant to avoid this, depending on manufacturer determination. If the system is used as a validated system for GMP metrics, the system must comply with regulations like 21 CFR Part 11.

When adding a sentinel to a validated legacy line, companies must consider revalidation or formal change control. The addition is typically handled under the site’s quality change management system and justified through risk assessment. Regulatory affairs should be consulted to ensure compliance with filing requirements.

Ongoing maintenance includes calibration (if applicable), periodic challenge tests, and preventive maintenance. Changes in product may require updating recognition algorithms and running a mini-OQ for that product.

In conclusion, the sentinel must be treated as GMP critical with full validation rigor if intended to act as a system that makes accept/reject decisions, alters flow determining disposition, replaces/redefines validated inspection, writes GMP batch release records, or exists as a required inspection step. If it does not do these things and acts solely as an advisory observer, CDMOs may choose to relax revalidation efforts commensurate with risk.

10. Operational and Economic Considerations

Introducing a sentinel inspection layer on a production line carries both operational implications and economic impacts. On the operational side, companies plan for production routines, maintenance schedules, and personnel responsibilities. Economically, they evaluate implementation cost versus benefits in risk reduction, quality improvement, and cost avoidance.

Operational considerations

• Staff training and SOPs: training, daily checks, review of flagged items, and updated procedures.
• Yield and throughput: impact depends on flag rate and tuning; benefit includes earlier detection of upstream issues.
• Maintenance and downtime: align with PM windows; define bypass procedures governed by quality approval.
• Data handling and review: logs, images, trending, and QA oversight can drive continuous improvement.

Economic considerations

• Capital and implementation costs: equipment, integration, validation effort, and change parts.
• Avoidance of regulatory enforcement: reducing risk of severe actions and operational disruption.
• Product waste vs. protection: false positives have labor/yield implications; tuning matters.
• Improved yield long-term: defect trend data can identify root causes and reduce waste over time.
• Intangible benefits: reputation, trust, and differentiating quality posture.
• ROI framing: preventing even one major event can justify investment over years.

Ultimately, the Sentinel Model is framed as an investment in robustness and reliability: it may add cost and complexity, but guards against greater crises that can arise in its absence.

11. Use Cases and Application Scenarios

Use Case 1: Regulatory compliance and audit readiness

A firm with a history of FDA 483 observations implements a Sentinel Model system as part of remediation. During the next inspection, they demonstrate live detection and advisory logs compared against GMP records. The system supports audit readiness and demonstrates proactive modernization and enhanced oversight.

Use Case 2: Legacy tablet press upgrade

A legacy tablet press line integrates a Sentinel inspection unit after manual inspection. The unit flags a low defect rate that reveals a punch misalignment pattern. Maintenance resolves the root cause; the sentinel remains as insurance while extending legacy equipment viability.

Use Case 3: High-risk product oversight

A potent oncology capsule product uses a dual approach: weight checking and packaging vision verification. Under-filled capsules and unexpected capsule color are detected and addressed before distribution. This illustrates layered controls where consequences of defects are especially severe.

Use Case 4: Continuous improvement and remote monitoring

A multi-site manufacturer deploys Sentinel systems and uses centralized analytics to compare trends. One site’s elevated coating blemishes lead to knowledge transfer and process adjustment. The sentinel enables enterprise-wide quality analytics and supports Pharma 4.0 transformation themes.

These scenarios demonstrate Sentinel versatility: preventing errors, extending legacy assets, managing high-risk products, and enabling continuous improvement.

12. Conclusion: Strengthening Confidence Without Disruption

Confidence from regulators, healthcare providers, and patients is built on a demonstrated commitment to quality and safety. The adoption of a Sentinel Model for structural inspection risk mitigation on solid oral dose lines is presented as a clear example of such commitment. By adding an intelligent, independent layer of oversight, companies can strengthen assurance of product quality without fundamentally disrupting existing processes.

Modernization does not require starting from scratch. Legacy lines can be augmented rather than replaced, addressing gaps like manual inspection limitations with advanced solutions. This achieves strengthening confidence without disruption: continuity of validated equipment and workflows, with increased quality signals.

From a regulatory standpoint, risk-based enhancements align with current expectations. Proactive strengthening of inspection controls can improve audit narratives and demonstrate state of control. Operationally, the Sentinel Model is designed to complement human judgment, automating repetitive detection and freeing humans for oversight and improvement.

For executives and investors, the business case is framed as risk reduction against costly events and reputational damage. Robust safeguards protect reliability and supply continuity while avoiding major rebuilds.

Implementation decisions, validation scope, and regulatory impact should always be determined by the manufacturer’s quality unit in consultation with regulatory affairs.

13. Appendix

The following sources were listed in the paper’s appendix. They are presented here as a linked reference list.

Glossary

cGMP: current Good Manufacturing Practice. Refers to FDA/ICH regulations and guidelines that outline minimum requirements for methods, facilities, and controls used in manufacturing, processing, and packing of pharmaceutical products to ensure quality and safety. For drugs, key regulations are in 21 CFR Parts 210–211.

CGMP for the 21st Century: An FDA initiative (circa 2002–2004) encouraging a modern, risk-based pharmaceutical quality paradigm with increased focus on process understanding, PAT, and QbD approaches.

QbD (Quality by Design): A development and manufacturing approach where quality is built into products by understanding the process and controlling variability rather than relying solely on end testing. Introduced in ICH Q8; closely related to ICH Q9 and ICH Q10.

Quality Risk Management (QRM): A systematic process for assessment, control, communication, and review of risks to quality, guided by ICH Q9.

ICH Q9(R1): The ICH guideline on Quality Risk Management revised in 2023 (R1), emphasizing that formality should be commensurate with risk and that risk-based decision-making underpins quality decisions.

ICH Q10: ICH guideline on Pharmaceutical Quality System, encouraging lifecycle management and continual improvement.

PAT (Process Analytical Technology): A system of building quality into processes via real-time measurements and controls of critical process parameters and attributes.

CAPA: Corrective and Preventive Action.

Form FDA 483: Form used by FDA investigators to document inspection observations.

False positive/false reject: In automated inspection, incorrectly identifying a good product as defective, leading to unwarranted rejection.

MES: Manufacturing Execution System.

SCADA: Supervisory Control and Data Acquisition.

OOS / OOT: Out of Specification / Out of Trend.

Methodology

This white paper’s analysis was supported by both data review and literature research. FDA’s Recalls Database (2017–2025) was analyzed, focusing on drug product recalls involving solid oral dosage forms (tablets and capsules). The review identified common failure modes such as labeling errors leading to product mix-ups and contamination/impurity issues. Case studies like the dronabinol/ziprasidone mix-up and tacrolimus empty capsules recall were drawn from FDA recall announcements to ground the discussion in actual events.

Industry guidance documents and articles were consulted to capture the current regulatory and technological environment. Sources included FDA guidance on quality systems and risk management (to align with ICH Q9/Q10), and publications from industry groups and trade journals discussing trends in automation and inspection. These provided insight into modern visual inspection capabilities, human vs. machine performance, and implementation considerations on legacy lines.

Real-world applications were incorporated as generalized scenarios. The combination of data (recall statistics, cost figures) and qualitative insights (guidelines and expert commentary) was used to ensure recommendations and conclusions are evidence-based and relevant as of 2025.